Literature DB >> 22426259

Pretreatment high-resolution rectal MRI and treatment response to neoadjuvant chemoradiation.

George J Chang1, Y Nancy You, In Ja Park, Harmeet Kaur, Chung-Yuan Hu, Miguel A Rodriguez-Bigas, John M Skibber, Randy D Ernst.   

Abstract

BACKGROUND: Use of rectal MRI evaluation of patients with rectal cancer for primary tumor staging and for identification for poor prognostic features is increasing. MR imaging permits precise delineation of tumor anatomy and assessment of mesorectal tumor penetration and radial margin risk.
OBJECTIVE: The aim of this study was to evaluate the ability of pretreatment rectal MRI to classify tumor response to neoadjuvant chemoradiation.
DESIGN: This study is a retrospective, consecutive cohort study and central review.
SETTING: This study was conducted at a tertiary academic hospital. PATIENTS: Sixty-two consecutive patients with locally advanced (stage cII to cIII) rectal cancer who underwent rectal cancer protocol high-resolution MRI before surgery (December 2009 to March 2011) were included. MAIN OUTCOME MEASURES: The primary outcomes measured were the probability of good (ypT0-2N0) vs poor (≥ypT3N0) response as a function of mesorectal tumor depth, lymph node status, extramural vascular invasion, and grade assessed by uni- and multivariate logistic regression.
RESULTS: Tumor response was good in 25 (40.3%) and poor in 37 (59.7%). Median interval from MRI to surgery was 7.9 weeks (interquartile range, 7.0-9.0). MRI tumor depth was <1 mm in 10 (16.9%), 1 to 5 mm in 30 (50.8%), and >5 mm in 21 (33.9%). Lymph node status was positive in 40 (61.5%), and vascular invasion was present in 16 (25.8%). Tumor response was associated with MRI tumor depth (p = 0.001), MRI lymph node status (p < 0.001) and vascular invasion (p = 0.009). Multivariate regression indicated >5 mm MRI tumor depth (OR = 0.08; 95% CI = 0.01-0.93; p = 0.04) and MRI lymph node positivity (OR = 0.12; 95% CI = 0.03-0.53; p = 0.005) were less likely to achieve a good response to neoadjuvant chemoradiotherapy. LIMITATIONS: Generalizability is uncertain in centers with limited experience with MRI staging for rectal cancer.
CONCLUSION: MRI assessment of tumor depth and lymph node status in rectal cancer is associated to tumor response to neoadjuvant chemoradiotherapy. These factors should therefore be considered for stratification of patients for novel treatment strategies reliant on pathologic response to treatment or for the selection of poor-risk patients for intensified treatment regimens.

Entities:  

Mesh:

Year:  2012        PMID: 22426259      PMCID: PMC3546551          DOI: 10.1097/DCR.0b013e31824678e3

Source DB:  PubMed          Journal:  Dis Colon Rectum        ISSN: 0012-3706            Impact factor:   4.585


  18 in total

1.  Clinical and pathologic predictors of locoregional recurrence, distant metastasis, and overall survival in patients treated with chemoradiation and mesorectal excision for rectal cancer.

Authors:  Prajnan Das; John M Skibber; Miguel A Rodriguez-Bigas; Barry W Feig; George J Chang; Paulo M Hoff; Cathy Eng; Robert A Wolff; Nora A Janjan; Marc E Delclos; Sunil Krishnan; Lawrence B Levy; Lee M Ellis; Christopher H Crane
Journal:  Am J Clin Oncol       Date:  2006-06       Impact factor: 2.339

2.  Preoperative versus postoperative chemoradiotherapy for rectal cancer.

Authors:  Rolf Sauer; Heinz Becker; Werner Hohenberger; Claus Rödel; Christian Wittekind; Rainer Fietkau; Peter Martus; Jörg Tschmelitsch; Eva Hager; Clemens F Hess; Johann-H Karstens; Torsten Liersch; Heinz Schmidberger; Rudolf Raab
Journal:  N Engl J Med       Date:  2004-10-21       Impact factor: 91.245

3.  Prognostic significance of magnetic resonance imaging-detected extramural vascular invasion in rectal cancer.

Authors:  N J Smith; Y Barbachano; A R Norman; R I Swift; A M Abulafi; G Brown
Journal:  Br J Surg       Date:  2008-02       Impact factor: 6.939

4.  A pathologic complete response to preoperative chemoradiation is associated with lower local recurrence and improved survival in rectal cancer patients treated by mesorectal excision.

Authors:  Julio García-Aguilar; Enrique Hernandez de Anda; Prayuth Sirivongs; Suk-Hwan Lee; Robert D Madoff; David A Rothenberger
Journal:  Dis Colon Rectum       Date:  2003-03       Impact factor: 4.585

5.  Diagnostic accuracy of preoperative magnetic resonance imaging in predicting curative resection of rectal cancer: prospective observational study.

Authors: 
Journal:  BMJ       Date:  2006-09-19

6.  Number of lymph nodes examined and prognosis among pathologically lymph node-negative patients after preoperative chemoradiation therapy for rectal adenocarcinoma.

Authors:  Chiaojung Jillian Tsai; Christopher H Crane; John M Skibber; Miguel A Rodriguez-Bigas; George J Chang; Barry W Feig; Cathy Eng; Sunil Krishnan; Dipen M Maru; Prajnan Das
Journal:  Cancer       Date:  2011-02-15       Impact factor: 6.860

7.  Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long-term results.

Authors:  Angelita Habr-Gama; Rodrigo Oliva Perez; Wladimir Nadalin; Jorge Sabbaga; Ulysses Ribeiro; Afonso Henrique Silva e Sousa; Fábio Guilherme Campos; Desidério Roberto Kiss; Joaquim Gama-Rodrigues
Journal:  Ann Surg       Date:  2004-10       Impact factor: 12.969

Review 8.  Neoadjuvant chemoradiation and local excision for T2-3 rectal cancer.

Authors:  Thomas Borschitz; Daniel Wachtlin; Markus Möhler; Heinz Schmidberger; Theodor Junginger
Journal:  Ann Surg Oncol       Date:  2007-12-28       Impact factor: 5.344

9.  Lymph node status after neoadjuvant radiotherapy for rectal cancer is a biologic predictor of outcome.

Authors:  George J Chang; Miguel A Rodriguez-Bigas; Cathy Eng; John M Skibber
Journal:  Cancer       Date:  2009-12-01       Impact factor: 6.860

Review 10.  A systematic approach to the interpretation of preoperative staging MRI for rectal cancer.

Authors:  Fiona G M Taylor; Robert I Swift; Lennart Blomqvist; Gina Brown
Journal:  AJR Am J Roentgenol       Date:  2008-12       Impact factor: 3.959

View more
  6 in total

Review 1.  Beyond Histologic Staging: Emerging Imaging Strategies in Colorectal Cancer with Special Focus on Magnetic Resonance Imaging.

Authors:  Tyler J Fraum; Joseph W Owen; Kathryn J Fowler
Journal:  Clin Colon Rectal Surg       Date:  2016-09

2.  Value of Primary Rectal Tumor PET/MRI in the Prediction of Synchronic Metastatic Disease.

Authors:  Marcelo A Queiroz; Cinthia D Ortega; Felipe R Ferreira; Fernanda C Capareli; Sergio C Nahas; Giovanni G Cerri; Carlos A Buchpiguel
Journal:  Mol Imaging Biol       Date:  2021-11-09       Impact factor: 3.488

3.  Transrectal ultrasound and magnetic resonance imaging measurement of extramural tumor spread in rectal cancer.

Authors:  Søren R Rafaelsen; Chris Vagn-Hansen; Torben Sørensen; John Pløen; Anders Jakobsen
Journal:  World J Gastroenterol       Date:  2012-09-28       Impact factor: 5.742

4.  Comparative analysis of lymph node metastases in patients with ypT0-2 rectal cancers after neoadjuvant chemoradiotherapy.

Authors:  In Ja Park; Y Nancy You; John M Skibber; Miguel A Rodriguez-Bigas; Barry Feig; Sa Nguyen; Chung-Yuan Hu; George J Chang
Journal:  Dis Colon Rectum       Date:  2013-02       Impact factor: 4.585

Review 5.  New Perspectives on Predictive Biomarkers of Tumor Response and Their Clinical Application in Preoperative Chemoradiation Therapy for Rectal Cancer.

Authors:  Nam Kyu Kim; Hyuk Hur
Journal:  Yonsei Med J       Date:  2015-11       Impact factor: 2.759

6.  Extramural depth of rectal cancer tumor invasion at thin-section MRI: predicting treatment response to neoadjuvant chemoradiation.

Authors:  Tong Tong; Yiqun Sun; Sanjun Cai; Zhen Zhang; Yajia Gu
Journal:  Oncotarget       Date:  2015-10-06
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.